TRACE: Tirapazamine-Radiation And Cisplatin Evaluation

Inclusion Criteria: * Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. * Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease). * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * Absolute neutrophil count at least 1.5 X 10\^9/L, platelet count at least 100 X 10\^9/L, and hemoglobin \> 9g/dL. * Serum bilirubin \< 1.25 times upper limit of normal (ULN) and aspartate aminotransferase (AST)/alanine transaminase (ALT) \< 2.5 times ULN. * Calculated creatinine clearance (Cockcroft-Gault) \> 55 mL/min. Exclusion Criteria: * Metastatic Disease * Primary cancers of the nasal and paranasal cavities and of the nasopharynx * Significant intercurrent illness that will interfere with the Chemotherapy or Radiation Therapy during the trial * Symptomatic peripheral neuropathy \> grade 2 * Clinically significant hearing impairment * Significant cardiac disease